Table 1.
Com | X | R | R1 | R2 | IC50 (µM)a | ||
---|---|---|---|---|---|---|---|
MDA-MB-231 | T-47D | MCF-10A | |||||
9a | F | H | H | H | 19.84 ± 1.08 | NAb | NDc |
9b | F | H | H | OH | 12.24 ± 0.67 | 18.61 ± 0.87 | NDc |
9c | F | H | H | N(CH3)2 | 2.54 ± 0.138 | 8.45 ± 0.27 | 47.03 ± 3.52 |
9d | F | OMe | H | H | 45.02 ± 2.45 | NAb | NDc |
9e | F | H | H | OMe | 14.13 ± 0.77 | 12.37 ± 0.33 | NDc |
9f. | F | OH | OMe | H | 3.40 ± 0.185 | 27.1 ± 1.08 | 42.60 ± 2.81 |
9g | F | H | OH | OMe | 0.62 ± 0.03 | 3.14 ± 0.11 | 31.74 ± 3.10 |
9h | F | H | OMe | OH | 5.82 ± 0.317 | 11.42 ± 0.67 | 79.45 ± 5.27 |
9i | Cl | H | H | H | 24.68 ± 1.35 | NAb | NDc |
9j | Cl | H | H | OH | 6.24 ± 0.34 | 35.10 ± 2.04 | 65.37 ± 5.04 |
9k | Cl | H | H | N(CH3)2 | 1.14 ± 0.06 | 4.92 ± 0.28 | 58.51 ± 4.36 |
9l | Cl | OMe | H | H | 58.01 ± 3.16 | NAb | NDc |
9m | Cl | H | H | OMe | 18.95 ± 1.03 | 27.63 ± 1.24 | NDc |
9n | Cl | OH | OMe | H | 35.15 ± 1.916 | 67.29 ± 2.51 | NDc |
9o | Cl | H | OH | OMe | 10.81 ± 0.59 | 7.36 ± 0.30 | NDc |
9p | Cl | H | OMe | OH | 6.55 ± 0.357 | 19.47 ± 0.92 | 83.62 ± 6.74 |
Doxorubicin | – | – | – | – | 3.67 ± 0.20 | 2.73 ± 0.09 | NDc |
Erolitinib | – | – | – | – | 2.88 ± 0.17 | 3.61 ± 0.24 |
aIC50 value is the mean ± S.D. of 3 separate experiments.
bNA: Derivatives with IC50 more than 100 mM.
cND: Not determined.